219 related articles for article (PubMed ID: 21788403)
1. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target.
Van Houdt WJ; Emmink BL; Pham TV; Piersma SR; Verheem A; Vries RG; Fratantoni SA; Pronk A; Clevers H; Borel Rinkes IH; Jimenez CR; Kranenburg O
Mol Cell Proteomics; 2011 Dec; 10(12):M111.011353. PubMed ID: 21788403
[TBL] [Abstract][Full Text] [Related]
2. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
Emmink BL; Van Houdt WJ; Vries RG; Hoogwater FJ; Govaert KM; Verheem A; Nijkamp MW; Steller EJ; Jimenez CR; Clevers H; Borel Rinkes IH; Kranenburg O
Gastroenterology; 2011 Jul; 141(1):269-78. PubMed ID: 21459094
[TBL] [Abstract][Full Text] [Related]
3. The secretome of colon cancer stem cells contains drug-metabolizing enzymes.
Emmink BL; Verheem A; Van Houdt WJ; Steller EJ; Govaert KM; Pham TV; Piersma SR; Borel Rinkes IH; Jimenez CR; Kranenburg O
J Proteomics; 2013 Oct; 91():84-96. PubMed ID: 23835434
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
5. ER-Stress-Induced Differentiation Sensitizes Colon Cancer Stem Cells to Chemotherapy.
Wielenga MCB; Colak S; Heijmans J; van Lidth de Jeude JF; Rodermond HM; Paton JC; Paton AW; Vermeulen L; Medema JP; van den Brink GR
Cell Rep; 2015 Oct; 13(3):489-494. PubMed ID: 26456824
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of Clonogenic KIT(+) Human Colon Tumor Cells Requires Secretion of Stem Cell Factor by Differentiated Tumor Cells.
Fatrai S; van Schelven SJ; Ubink I; Govaert KM; Raats D; Koster J; Verheem A; Borel Rinkes IH; Kranenburg O
Gastroenterology; 2015 Sep; 149(3):692-704. PubMed ID: 25962936
[TBL] [Abstract][Full Text] [Related]
7. FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Bae KB; Park YH; Kim SU; Kim JM; Kim N; Ko KS; Rhee BD; Han J
Gastroenterology; 2015 Oct; 149(4):1006-16.e9. PubMed ID: 26091938
[TBL] [Abstract][Full Text] [Related]
8. Human colonic fibroblasts regulate stemness and chemotherapy resistance of colon cancer stem cells.
Colak S; Medema JP
Cell Cycle; 2016 Jun; 15(12):1531-7. PubMed ID: 25483065
[TBL] [Abstract][Full Text] [Related]
9. Verticillin A overcomes apoptosis resistance in human colon carcinoma through DNA methylation-dependent upregulation of BNIP3.
Liu F; Liu Q; Yang D; Bollag WB; Robertson K; Wu P; Liu K
Cancer Res; 2011 Nov; 71(21):6807-16. PubMed ID: 21911457
[TBL] [Abstract][Full Text] [Related]
10. Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery.
Fang DD; Kim YJ; Lee CN; Aggarwal S; McKinnon K; Mesmer D; Norton J; Birse CE; He T; Ruben SM; Moore PA
Br J Cancer; 2010 Apr; 102(8):1265-75. PubMed ID: 20332776
[TBL] [Abstract][Full Text] [Related]
11. SW480 colorectal cancer cells that naturally express Lgr5 are more sensitive to the most common chemotherapeutic agents than Lgr5-negative SW480 cells.
Planutis AK; Holcombe RF; Planoutene MV; Planoutis KS
Anticancer Drugs; 2015 Oct; 26(9):942-7. PubMed ID: 26196680
[TBL] [Abstract][Full Text] [Related]
12. Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines.
Liu Z; Qiu M; Tang QL; Liu M; Lang N; Bi F
Chin J Cancer; 2010 Jul; 29(7):661-7. PubMed ID: 20591218
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C
Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801
[TBL] [Abstract][Full Text] [Related]
14. The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.
Luk SU; Xue H; Cheng H; Lin D; Gout PW; Fazli L; Collins CC; Gleave ME; Wang Y
Oncotarget; 2014 Aug; 5(16):6896-908. PubMed ID: 25071009
[TBL] [Abstract][Full Text] [Related]
15. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells.
Ding ZY; Liu GH; Olsson B; Sun XF
Tumour Biol; 2013 Apr; 34(2):683-93. PubMed ID: 23188704
[TBL] [Abstract][Full Text] [Related]
17. Proteome of human colon cancer stem cells: a comparative analysis.
Zou J; Yu XF; Bao ZJ; Dong J
World J Gastroenterol; 2011 Mar; 17(10):1276-85. PubMed ID: 21455326
[TBL] [Abstract][Full Text] [Related]
18. Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells.
Oh PS; Patel VB; Sanders MA; Kanwar SS; Yu Y; Nautiyal J; Patel BB; Majumdar AP
Am J Physiol Gastrointest Liver Physiol; 2011 Aug; 301(2):G347-55. PubMed ID: 21596996
[TBL] [Abstract][Full Text] [Related]
19. Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
Raghavan S; Mehta P; Ward MR; Bregenzer ME; Fleck EMA; Tan L; McLean K; Buckanovich RJ; Mehta G
Clin Cancer Res; 2017 Nov; 23(22):6934-6945. PubMed ID: 28814433
[No Abstract] [Full Text] [Related]
20. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis.
Huerta S; Harris DM; Jazirehi A; Bonavida B; Elashoff D; Livingston EH; Heber D
Int J Oncol; 2003 Mar; 22(3):663-70. PubMed ID: 12579322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
